Search Orphan Drug Designations and Approvals
-
Generic Name: | nanatinostat and valganciclovir |
---|---|
Date Designated: | 02/28/2019 |
Orphan Designation: | Treatment of plasmablastic lymphoma |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Viracta Therapeutics, Inc. 2533 South Coast Highway Suite 210 Cardiff, California 92007 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-